ReviewMedicina (Kaunas, Lithuania)2026
Current Advancements in Bone Grafting Substitutes for Osteoporotic Distal Tibia Fractures: A Narrative Review of Beta-Tricalcium Phosphate (Neobone™) and Demineralized Bone Matrix.
Review in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The surgical management of distal tibia fractures in the elderly is increasingly complex due to the rising prevalence of osteoporosis and the unique anatomical constraints of the region. While autologous bone graft remains the gold standard, its limitations have led to the widespread adoption of synthetic and biological substitutes. This narrative review explores the current trends in bone grafting for osteoporotic distal tibia fractures, focusing on pure β-tricalcium phosphate (β-TCP) and demineralized bone matrix (DBM). We specifically examine the biological mechanisms, resorption kinetics, and clinical outcomes of these materials. Furthermore, we highlight the emerging clinical preference for powder-type pure β-TCP (Neobone™) due to its superior surface area and packing efficiency in irregular metaphyseal voids. Powder-type pure β-TCP demonstrates superior packing efficiency and predictable resorption kinetics for metaphyseal void filling, while DBM remains a context-dependent biological supplement. Ion-substituted TCP formulations, pharmacological augmentation, and hybrid scaffolds are highlighted as future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.